David S Hong
Stanford University · ECOG-ACRIN Cancer Research Group · M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
27
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
1 more share only the name and are not shown
Trial papers in non-small cell lung cancer
20
PubMed author-name match
Trials
Studies that name David S Hong as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:44 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07155707 · Phase II: Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical SettingsStanford University · recruiting · Anxiety, Mood Disorders · principal investigator
- Ph2NCT06390852 · Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma · principal investigator
- N/ANCT06364137 · Engagement and Clinical Impact of the Teleo Virtual Therapy Platform in Clinical SettingsStanford University · completed · Anxiety Disorders, Mood Disorders · principal investigator
- Ph2NCT06360575 · Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma · principal investigator
- Ph2NCT06357975 · Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)National Cancer Institute (NCI) · active not recruiting · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma · principal investigator
- Ph1NCT05722327 · Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal CancerM.D. Anderson Cancer Center · active not recruiting · Colon Cancer, Colorectal Cancer · principal investigator
- Ph2NCT04879121 · Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid TumorsM.D. Anderson Cancer Center · recruiting · Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph1NCT03290937 · Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal CancerM.D. Anderson Cancer Center · completed · Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8 · principal investigator
- Ph2NCT02983578 · Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerM.D. Anderson Cancer Center · active not recruiting · Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Carcinoma · principal investigator
- Ph1NCT02942095 · Study of Ixazomib and Erlotinib in Solid TumorsM.D. Anderson Cancer Center · completed · Solid Tumors · principal investigator
- Ph1NCT02915172 · Lenvatinib and Capecitabine in Patients With Advanced MalignanciesM.D. Anderson Cancer Center · withdrawn · Advanced Cancer, Malignant Neoplasm of Breast, Malignant Neoplasms of Bone and Articular Cartilage · principal investigator
- Ph1NCT02668770 · Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid MalignanciesM.D. Anderson Cancer Center · terminated · Advanced Cancers, Melanoma · principal investigator
- Ph2NCT02478320 · Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid TumorsM.D. Anderson Cancer Center · terminated · Advanced Cancers · principal investigator
- Ph1NCT01787500 · Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by SurgeryM.D. Anderson Cancer Center · completed · BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph1NCT01744652 · Dasatinib and Crizotinib in Advanced CancerM.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT01738139 · Ipilimumab and Imatinib Mesylate in Advanced CancerM.D. Anderson Cancer Center · completed · Advanced Malignant Solid Neoplasm, C-KIT Tyrosine Kinase Protein Overexpression, Clinical Stage IV Cutaneous Melanoma AJCC v8 · principal investigator
- Ph1NCT01608139 · Study of Curcumin, Vorinostat, and SorafenibM.D. Anderson Cancer Center · withdrawn · Advanced Cancers · principal investigator
- Ph1NCT01454804 · Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid TumorsM.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT01430572 · Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss PatientsM.D. Anderson Cancer Center · completed · Advanced Cancers, Solid Tumors · principal investigator
- Ph1NCT01201694 · Phase I Study of Surface-Controlled Water Soluble Curcumin (THERACURMIN CR-011L)M.D. Anderson Cancer Center · completed · Advanced Cancers · principal investigator
- Ph1NCT01113476 · Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced MalignanciesM.D. Anderson Cancer Center · completed · Advanced Cancer · study chair
- Ph1NCT01087554 · Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced CancerM.D. Anderson Cancer Center · active not recruiting · Advanced Cancer · principal investigator
- Ph1NCT00955812 · STAT3 Inhibitor for Solid TumorsM.D. Anderson Cancer Center · completed · Advanced Cancer, Solid Tumor · principal investigator
- Ph1NCT00554268 · Trial of PBI-05204 in Advanced Cancer PatientsM.D. Anderson Cancer Center · completed · Solid Tumors · principal investigator
- Ph1NCT00508807 · RTA 402 in Advanced Solid Tumors or Lymphoid MalignanciesM.D. Anderson Cancer Center · completed · Lymphoid Malignancies, Solid Tumors · principal investigator
- Ph1NCT00431054 · Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian CancerM.D. Anderson Cancer Center · completed · Ovarian Cancer · principal investigator
- Ph1NCT00429234 · Gemcitabine and Dasatinib in Advanced Solid TumorsM.D. Anderson Cancer Center · completed · Advanced Cancer, Solid Tumors · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Engagement and clinical impact of the Teleo virtual therapy platform in clinical settingsR42MH136878 · NIMH · MAINSQUARE CO · fiscal years 2024 to 2026 · $1,044,386 awarded in 2026Grant number is on one of their registry trials
- Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $476,200 awarded in 2026Same name and institution; not confirmed by an ID
- Research Training for Child Psychiatry and NeurodevelopmentT32MH019908 · NIMH · STANFORD UNIVERSITY · fiscal years 2026 · $344,085 awarded in 2026Same name and institution; not confirmed by an ID
- 12 Clinical and Translational Research CenterP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2022 to 2025 · $379,325 awarded in 2025Grant number is on one of their registry trials
- Use of Patient-Reported Outcomes in Understanding Symptomatic Adverse Events in Early-Phase Trials of Combination Treatments that Include Immune Checkpoint Inhibitors and Targeted TherapyR01CA242565 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2019 to 2025 · $218,645 awarded in 2025Same name and institution; not confirmed by an ID
- Sex hormone effects on neurodevelopment: Controlled puberty in transgender adolescentsR01MH115349 · NIMH · STANFORD UNIVERSITY · fiscal years 2018 to 2023 · $707,054 awarded in 2023Same name and institution; not confirmed by an ID
- Therapeutic Strategies for Patients With BRAF Mutant Colorectal CancerR01CA187238 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2014 to 2018 · $332,000 awarded in 2018Grant number is on one of their registry trials
- Neuroanatomical substrates of cognition in mosaic Turner syndromeK23MH097120 · NIMH · STANFORD UNIVERSITY · fiscal years 2012 to 2015 · $181,410 awarded in 2015Same name and institution; not confirmed by an ID
- Mechanisms of B Cell Responses to a Novel Adjuvant for Influenza VaccineK08AI079269 · NIAID · STANFORD UNIVERSITY · fiscal years 2008 to 2012 · $130,599 awarded in 2012Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- ECOG-ACRIN Network Group Operations CenterU10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026
Most cited trial papers
Clinical-trial papers with this author name in non-small cell lung cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:44 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med · 20201,444 citationsRCR 58.9
- Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.Lancet Oncol · 2019210 citationsRCR 8.0
- A first-in-human study of conatumumab in adult patients with advanced solid tumors.Clin Cancer Res · 2010118 citationsRCR 2.5
- Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.J Clin Oncol · 2023105 citationsRCR 8.9
- Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial.Ann Oncol · 202087 citationsRCR 3.5
- High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial.Radiother Oncol · 202185 citationsRCR 3.8
- Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.Clin Cancer Res · 202172 citationsRCR 3.7
- Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.Clin Cancer Res · 201871 citationsRCR 2.0
- Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer.Invest New Drugs · 201557 citationsRCR 1.6
- MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.J Thorac Oncol · 202334 citationsRCR 2.0